Trevi Therapeutics, Inc.
NASDAQ:TRVI
3.5 (USD) • At close September 19, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Omzet
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 0.123 | 0.043 | 0.05 | 0.047 | 0.039 | 0.023 | 0 | 0.004 |
| Brutowinst
| -0.123 | -0.043 | -0.05 | -0.047 | -0.039 | -0.023 | 0 | -0.004 |
| Brutowinstmarge
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 23.683 | 19.834 | 22.984 | 22.328 | 19.339 | 14.072 | 6.095 | 6.913 |
| Algemene en administratieve kosten
| 9.953 | 10.073 | 9.492 | 10.161 | 7.306 | 4.336 | 2.142 | 1.658 |
| Verkoop- en marketingkosten
| -0.123 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 |
| Verkoop-, algemene en administratieve kosten
| 10.117 | 10.073 | 9.492 | 10.161 | 7.306 | 4.336 | 2.142 | 1.708 |
| Overige kosten
| 0 | 0.719 | -0.375 | -0.287 | 0.577 | -2.243 | -0.024 | 0 |
| Bedrijfskosten
| 33.8 | 29.907 | 32.476 | 32.489 | 26.645 | 18.408 | 8.237 | 8.621 |
| Bedrijfsresultaat
| -33.923 | -29.907 | -32.476 | -32.489 | -26.645 | -18.408 | -8.237 | -8.625 |
| Bedrijfsresultaat ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 4.826 | 0.719 | -1.485 | -0.287 | 0.577 | -2.243 | -1.376 | -2.47 |
| Inkomen voor belasting
| -29.097 | -29.188 | -33.961 | -32.776 | -26.068 | -20.669 | -12.886 | -11.095 |
| Inkomen voor belasting ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Belastingkosten
| -0.032 | -0.036 | -0.021 | -0.018 | -0.018 | -0.124 | -0.026 | -0.008 |
| Nettowinst
| -29.065 | -29.152 | -33.94 | -32.758 | -26.05 | -20.545 | -12.86 | -11.087 |
| Nettowinstmarge
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.29 | -0.45 | -1.49 | -1.81 | -2.22 | -2.29 | -1.43 | -0.69 |
| Verwaterde WPA
| -0.29 | -0.45 | -1.49 | -1.81 | -2.22 | -2.29 | -1.43 | -0.69 |
| EBITDA
| -33.8 | -29.907 | -32.791 | -32.489 | -26.645 | -20.472 | -8.188 | -8.621 |
| EBITDA ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |